Objective: The objective of this study is to systematically review the economic evaluations of
dapagliflozin in the treatment of patients with heart failure (HF) and describe their general …

Importance Recently, new drugs have been approved for the first-line treatment of metastatic
renal cell carcinoma (mRCC). Nivolumab plus ipilimumab significantly increases overall …

Background. Information regarding the impact of cardiovascular (CV) conditions on disease
progression among patients with mild coronavirus disease 2019 (COVID-19) is limited. …

Background The IMpower150 trial found that adding atezolizumab to the combination of
bevacizumab and chemotherapy improved survival for patients with metastatic, nonsquamous …

Introduction Lung cancer, the most prevalent malignant cancer in the world, remains a
serious threat to public health. Recently, a large number of studies have shown that an …

Background and Objective The economic assessment of immuno-oncology agents in
Chinese patients is limited despite a need for new therapies. Nivolumab is the first immune …

Background Postoperative adjuvant chemotherapy with capecitabine and oxaliplatin was
first recommended for resectable gastric cancer patients in the 2011 Chinese National …

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs.
chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (…

Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar
significantly improved the median progression-free survival and median overall survival (OS…

Background: An oncology trial compared four cycles of doxorubicin/cyclophosphamide (AC)
with four cycles of docetaxel/cyclophosphamide (TC) in operable breast cancer patients (71…